Subsequent Events	6 Months Ended
Jun. 30, 2024
Subsequent Events
Subsequent Events	15. Subsequent events On July 30, 2024 The Company received notice from the U.S. Food and Drug Administration (FDA) that it had been granted Rare Pediatric Drug Designation (RPDD) for VCN-01 for the treatment of retinoblastoma. VCN-01, the Company’s lead product candidate, is a systemic, selective, stroma-degrading oncolytic adenovirus. Previously, the FDA granted orphan drug designation to VCN-01 for treatment of retinoblastoma. On July 30, 2024, the Company received a notice of conversion from the holder of shares of its Series C Convertible Preferred Stock to convert the 135,431 shares of Series C Convertible Preferred Stock into 888,072 shares of the Company’s common stock at a conversion price of $1.22 per share. On July 31, 2024 the Company sold through the At Market Issuance Sales Agreement and the Amended and Restated Sales Agreement approximately 1.8 million shares of the Company’s common stock and received net proceeds of approximately $0.5 million. The Company previously had an option-license agreement with Massachusetts General Hospital to develop SYN-020 in several potential indications related to inflammation and gut barrier dysfunction. however, this expired in July 2024.

Subsequent Events

6 Months Ended

Jun. 30, 2024

15. Subsequent events

On July 30, 2024 The Company received notice from the U.S. Food and Drug Administration (FDA) that it had been granted Rare Pediatric Drug Designation (RPDD) for VCN-01 for the treatment of retinoblastoma. VCN-01, the Company’s lead product candidate, is a systemic, selective, stroma-degrading oncolytic adenovirus. Previously, the FDA granted orphan drug designation to VCN-01 for treatment of retinoblastoma.

On July 30, 2024, the Company received a notice of conversion from the holder of shares of its Series C Convertible Preferred Stock to convert the 135,431 shares of Series C Convertible Preferred Stock into 888,072 shares of the Company’s common stock at a conversion price of $1.22 per share.

On July 31, 2024 the Company sold through the At Market Issuance Sales Agreement and the Amended and Restated Sales Agreement approximately 1.8 million shares of the Company’s common stock and received net proceeds of approximately $0.5 million.

The Company previously had an option-license agreement with Massachusetts General Hospital to develop SYN-020 in several potential indications related to inflammation and gut barrier dysfunction. however, this expired in July 2024.